FrancophonIA/ELRC3.0 huggingface dataset:
English: In the 24-week clinical study, where Colobreathe was administered twice daily to adults and children aged 6-17, the adverse reactions identified in the paediatric population were similar to that for the overall population.
Slovenian: V 24-tedenski klinični študiji, kjer so zdravilo Colobreathe dajali dvakrat na dan odraslim in otrokom,
English: The other ingredients are: Capsule Shell Gelatin polyethylene glycol sodium lauryl sulfate purified water
Slovenian: Sestavine PEG-želatinskih trdih kapsul: želatina polietilenglikol prečiščena voda natrijev lavrilsulfat
English: Each capsule contains 1,662,500 IU, which is approximately equal to 125 mg of colistimethate sodium.
Slovenian: Ena kapsula vsebuje 1.662.500 i.e., kar ustreza približno 125 mg natrijevega kolistimetata.
English: Physico-chemical data suggest excretion of colistimethate sodium in human milk.
Slovenian: Dojenje Na podlagi fizikalno-kemijskih podatkov se predvideva izločanje natrijevega kolistimetata v materino mleko.
English: A systemic absorption study showed minimal urinary excretion with less than 3% of the dose of Colobreathe excreted in the urine as colistimethate sodium and colistin.
Slovenian: Manj kot 3 % odmerka so se izločili z urinom v obliki natrijevega kolistimetata in kolistina.
English: • if you/your child are taking colistimethate by injection or nebulisation caution must be taken;
Slovenian: • če vi ali vaš otrok uporabljate kolistimetat v obliki injekcij ali z nebulizatorjem, morate biti previdni;
English: Now replace the mouthpiece by screwing it back into place.
Slovenian: Znova namestite ustnik, tako da ga privijete nazaj na ustrezno mesto.
English: Colistimethate is not significantly absorbed from the lung after inhalation of Colobreathe.
Slovenian: Absorpcija kolistimetata iz pljuč po inhalaciji zdravila Colobreathe ni obsežna.
English: Absorption of colistimethate from the gastro-intestinal tract does not occur to any appreciable extent in the normal individual.
Slovenian: Absorpcija kolistimetata iz prebavil pri zdravih osebah ne poteka v omembe vrednem obsegu.
English: Preparing the Turbospin
Slovenian: Priprava inhalatorja Turbospin
English: Each capsule contains 1,662,500 IU (approximately equivalent to 125 mg) of colistimethate sodium.
Slovenian: Ena kapsula vsebuje 1.662.500 i.e. (kar ustreza približno 125 mg) natrijevega kolistimetata.
English: Caution should be taken with concomitant use of Colobreathe and parenteral or nebulised colistimethate sodium.
Slovenian: Pri sočasni uporabi zdravila Colobreathe in natrijevega kolistimetata, danega parenteralno ali z nebulizatorjem, je potrebna previdnost.
English: • Vomiting, nausea
Slovenian: • bruhanje, slabost,
English: Each 56 capsule pack contains one Turbospin powder inhaler device and 7 blisters of 8 capsules or one Turbospin powder inhaler device and 4 blisters of 14 capsules (56 hard capsules) sufficient for 4 weeks use.
Slovenian: Eno pakiranje s 56 kapsulami vsebuje en inhalator za prašek Turbospin in 7 pretisnih omotov z 8 kapsulami ali en inhalator za prašek Turbospin in 4 pretisne omote s 14 kapsulami (56 trdih kapsul),
English: No force is required.
Slovenian: Navedba smiselno ni potrebna.
English: Haemoptysis, bronchospasm, asthma, wheezing, chest discomfort, lower respiratory tract infection, productive cough, crackles lung
Slovenian: Bolezni dihal, prsnega koša in mediastinalnega prostora dispneja, kašelj, disfonija, draženje grla hemoptiza, bronhospazem, astma, sopenje, nelagodje v prsnem košu, okužba spodnjih dihal, produktiven kašelj,
English: Colobreathe is inhaled into the lungs as a powder from the capsule using the hand-held inhaler called the Turbospin.
Slovenian: Zdravilo Colobreathe v obliki praška iz kapsule se inhalira v pljuča z ročnim inhalatorjem, imenovanim Turbospin.
English: • Cough, throat irritation
Slovenian: • kašelj, draženje žrela,
English: Colobreathe capsules are to be used only with the Turbospin powder inhaler.
Slovenian: Zdravilo Colobreathe kapsule se uporabljajo samo z inhalatorjem za prašek Turbospin.
English: Do not swallow the capsules.
Slovenian: Kapsul ne zaužijte.
English: High concentrations of total free colistin (mean 23.5mg/L) and total colistimethate (mean 178mg/L) were observed in sputum at 1 hour post-dose on Day 8 following BID dosing for 7 days across all age groups.
Slovenian: Na 8. dan po 7-dnevnem odmerjanju dvakrat dnevno so v vseh starostnih skupinah 1 uro po odmerku opazili v sputumu visoke koncentracije celotnega prostega kolistina (srednja vrednost 23,5 mg/l) in celotnega kolistimetata (srednja vrednost 178 mg/l).
English: Weight fluctuation, decreased appetite
Slovenian: Presnovne in prehranske motnje nihanje telesne mase, zmanjšanje apetita
English: Clean the chamber using a tissue or cotton bud.
Slovenian: Komoro očistite s papirnatim robčkom ali kosmičem vate.
English: Unscrew the mouthpiece, exposing the chamber of the Turbospin inhaler.
Slovenian: Odvijte ustnik, da razkrijete komoro inhalatorja Turbospin.
English: • have reacted badly to inhaled dry powder medicines previously unless this has already been discussed with your doctor.
Slovenian: Povejte svojemu zdravniku, če je pri vas/vašem otroku pojavi kaj od naslednjega: • predhoden slab odziv na inhalirano zdravilo v obliki suhega praška, razen če ste se o tem že pogovorili s svojim zdravnikom;
English: • Excessive production of saliva
Slovenian: • pretirano izločanje sline,
English: The capsules must not be swallowed.
Slovenian: Izpiralne tekočine ne smete pogoltniti.
English: Taking Colobreathe using the Turbospin inhaler Preparing the Turbospin
Slovenian: Jemanje zdravila Colobreathe z uporabo inhalatorja Turbospin Priprava inhalatorja Turbospin
English: If you/your child needs to have other forms of colistimethate either by injection or nebulisation caution should be used but your doctor should be aware of this.
Slovenian: Če morate vi ali vaš otrok uporabljati kolistimetat v drugi obliki, z injiciranjem ali nebulizatorjem, morate biti previdni.
English: ( Mean)
Slovenian: (povprečje)
English: Taking Colobreathe using the Turbospin inhaler
Slovenian: Jemanje zdravila Colobreathe z uporabo inhalatorja Turbospin
English: The tiny particles of medication in the capsule are picked up by the airflow and carried down your airway into your lungs.
Slovenian: S pretokom zraka skozi dihalne poti se drobni delci zdravila prenesejo iz kapsule v pljuča.
English: The active substance is colistimethate sodium.
Slovenian: Zdravilna učinkovina je natrijev kolistimetat.
English: Balance disorder, headache
Slovenian: Bolezni živčevja motnje ravnotežja, glavobol konvulzije, somnolenca
English: Discard the Turbospin inhaler after the completion of a treatment pack.
Slovenian: Inhalator Turbospin zavrzite, ko porabite pakiranje zdravila.
English: Posology
Slovenian: Ustnik
English: Do not stop your treatment early unless your doctor says you can.
Slovenian: Če ste vi/vaš otrok prenehali uporabljati zdravilo Colobreathe Ne prenehajte z zdravljenjem, razen če vam zdravnik naroči, da lahko.
English: Therefore, dose adjustment in low age groups is considered not necessary.
Slovenian: Zato ni videti, da bi mlajši bolniki potrebovali prilagojen odmerek.
English: Colobreathe 1,662,500 IU inhalation powder, hard capsules
Slovenian: Colobreathe 1.662.500 i.e. prašek za inhaliranje, trde kapsule
English: • Toothache
Slovenian: • tesnoba,
English: Bronchospasm or coughing may occur on inhalation.
Slovenian: Po inhaliranju se lahko pojavi bronhospazem ali kašelj.
English: The rinse should not be swallowed.
Slovenian: Vode, s katero izpirate, ne smete pogoltniti.
English: Do not try to loosen the capsule by repeatedly pressing the piston.
Slovenian: Odstranite pokrovček tako, da ga nežno povlečete.
English: Skin rash may also indicate hypersensitivity and if this occurs treatment should be withdrawn.
Slovenian: Tudi kožni izpuščaj lahko nakazuje preobčutljivost.
English: Haemoptysis
Slovenian: Tobramicin
English: • Nose bleeds, catarrh (mucus in your nose, which may make you feel blocked up),
Slovenian: • krvavitev iz nosu, katar (sluz v nosu, zaradi katere čutite zamašenost), izkašljevanje goste zelene sluzi, bolečina v žrelu in sinusih,
English: Immune system disorders
Slovenian: Bolezni imunskega sistema preobčutljivost na zdravilo
English: Contents of the pack and other information
Slovenian: Shranjevanje zdravila Colobreathe Vsebina pakiranja in dodatne informacije
English: Colobreathe 1,662,500 IU inhalation powder, hard capsules colistimethate sodium
Slovenian: Colobreathe 1.662.500 i.e. prašek za inhaliranje, trde kapsule natrijev kolistimetat
English: Chest pain, dyspnoea exacerbated, pharyngolaryngeal pain, epistaxis, sputum purulent, abnormal chest sound, increased upper airway secretion
Slovenian: šumi v pljučih bolečina v prsnem košu, poslabšanje dispneje, faringolaringealna bolečina, epistaksa,
English: Colistimethate sodium is converted to the base in vivo.
Slovenian: Biotransformacija Natrijev kolistimetat se in vivo pretvori v kolistin.
English: Ear and labyrinth disorders
Slovenian: vključno z motnjami labirinta tinitus kongestija ušesa
English: • Sleepiness
Slovenian: • zasoplost,
English: Colobreathe 1,662,500 IU inhalation powder colistimethate sodium
Slovenian: Colobreathe 1.662.500 i.e. prašek za inhaliranje natrijev kolistimetat samo za inhaliranje
English: Medication error
Slovenian: NAČIN IZDAJANJA ZDRAVILA
English: You may see a small amount of powder released from the capsule chamber after the capsule is pierced, this is normal.
Slovenian: Po prebodu kapsule boste morda videli, kako se bo iz komore inhalatorja sprostil oblaček praška.
English: Package leaflet: Information for the user Colobreathe 1,662,500 IU inhalation powder, hard capsules
Slovenian: Navodilo za uporabo Colobreathe 1.662.500 i.e. prašek za inhaliranje, trde kapsule natrijev kolistimetat
English: • Chest pain
Slovenian: • krči,
English: patients
Slovenian: Zdravljenje
English: Gastrointestinal disorders
Slovenian: Psihiatrične motnje tesnoba
English: Vpriv velaglucerase alfa
Slovenian: Vpriv velagluceraza alfa
English: What measures are being taken to ensure the safe and effective use of Vpriv?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Vpriv?
English: The main measure of effectiveness was the improvement in anaemia, one of the symptoms of the disease, after 41 weeks.
Slovenian: Glavno merilo učinkovitosti je bilo izboljšanje anemije, ki je eden od simptomov bolezni, po 41 tednih zdravljenja.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Vpriv on 26 August 2010.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Vpriv, veljavno po vsej Evropski uniji, izdala 26. avgusta 2010.
English: The dose can be adjusted according to each patient's symptoms and response to treatment.
Slovenian: Odmerek se lahko prilagodi glede na simptome vsakega posameznega bolnika in njegov odziv na zdravljenje.
English: What benefit has Vpriv shown during the studies?
Slovenian: Kakšne koristi je zdravilo Vpriv izkazalo med študijami?
English: Other information about Vpriv
Slovenian: Druge informacije o zdravilu Vpriv
English: The most serious side effects are hypersensitivity (allergic) reactions.
Slovenian: Najresnejši neželeni učinki so preobčutljivostne (alergijske) reakcije.
English: Vpriv increased the amount of haemoglobin (the protein in red blood cells that carries oxygen) by an average of 1.6 grams per decilitre (from 11.4 g/dl) while imiglucerase increased the amount of haemoglobin by an average of 1.5 g/dl (from 10.6 g/dl).
Slovenian: Zdravilo Vpriv je količino hemoglobina (beljakovine v rdečih krvnih celicah, ki prenašajo kisik) v povprečju povečalo za 1,6 grama na deciliter (z vrednosti 11,4 g/dl), medtem ko je imigluceraza količino hemoglobina v povprečju povečala za 1,5 g/dl (z vrednosti 10,6 g/dl).
English: The recommended dose of Vpriv is 60 units/kg bodyweight, which is given as a one-hour infusion once every two weeks.
Slovenian: Priporočeni odmerek zdravila Vpriv je 60 enot/kg telesne mase, ki se daje v obliki enourne infuzije enkrat vsake dva tedna.
English: The study also looked at control of other signs of the disease such as the increase in the number of platelets in the blood, and the reduction of the size of the liver and spleen.
Slovenian: V študiji so proučevali tudi nadzor nad drugimi znaki bolezni, kot sta povečanje števila trombocitov v krvi ter zmanjšanje velikosti jeter in vranice.
English: The first three infusions are given in hospital, but subsequent infusions may be given at home in patients who tolerate the medicine well.
Slovenian: Prve tri infuzije se dajo v bolnišnici, a se lahko pri bolnikih, ki zdravilo dobro prenašajo, naslednje infuzije dajo v domači oskrbi.
English: In one main study involving 35 patients (including 9 children) with type 1 Gaucher disease, Vpriv was compared with imiglucerase (another medicine for Gaucher disease).
Slovenian: V eni glavni študiji, v katero je bilo vključenih 35 bolnikov (vključno z devetimi otroki) z Gaucherjevo boleznijo tipa 1, so zdravilo Vpriv primerjali z imiglucerazo (drugim zdravilom za zdravljenje Gaucherjeve bolezni).
English: For more information about treatment with Vpriv, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Vpriv preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: What is the risk associated with Vpriv?
Slovenian: Kakšna tveganja so povezana z zdravilom Vpriv?
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Vpriv is available on the Agency's website under EMA website/Find medicine/Human medicines/Rare disease designations.
Slovenian: Povzetek mnenja Odbora za zdravila sirote o zdravilu Vpriv je na voljo na spletni strani agencije EMA website/Find medicine/Human medicines/Rare disease designations.
English: This document is a summary of the European public assessment report (EPAR) for Vpriv.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Vpriv.
English: Velaglucerase alfa replaces the missing enzyme in Gaucher disease, helping to break down glucocerebroside and stopping it building up in the body.
Slovenian: Velagluceraza alfa nadomesti manjkajoči encim pri Gaucherjevi bolezni tako, da pomaga razgraditi glukocerebrozid in zaustavi njegovo kopičenje v telesu.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vpriv.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: The CHMP decided that Vpriv's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: CHMP je zaključil, da so koristi zdravila Vpriv večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
English: Because the number of patients with Gaucher disease is low, the disease is considered ‘rare', and Vpriv was designated an ‘orphan medicine' (a medicine used in rare diseases) on 9 June 2010.
Slovenian: Ker je bolnikov z Gaucherjevo boleznijo malo, velja ta bolezen za redko, zato je bilo zdravilo Vpriv 9. junija 2010 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
English: Vpriv must not be used in people who have a severe allergic reaction to velaglucerase alfa or any of the other ingredients.
Slovenian: Zdravila Vpriv ne smejo uporabljati osebe, ki imajo hudo alergijsko reakcijo na velaglucerazo alfa ali katero koli drugo sestavino zdravila.
English: Why has Vpriv been approved?
Slovenian: Zakaj je bilo zdravilo Vpriv odobreno?
English: Vpriv is used in patients who have type 1 Gaucher disease, the type that usually affects the liver, spleen and bones.
Slovenian: Zdravilo Vpriv se uporablja pri bolnikih, ki imajo Gaucherjevo bolezen tipa 1, ki običajno prizadene jetra, vranico in kosti.
English: The study also showed that Vpriv is as effective as imiglucerase in controlling other signs of Gaucher disease.
Slovenian: Študije so pokazale, da je zdravilo Vpriv enako učinkovito kot imigluceraza tudi pri nadzoru drugih simptomov Gaucherjeve bolezni.
English: Vpriv is a medicine that contains the active substance velaglucerase alfa.
Slovenian: Vpriv je zdravilo, ki vsebuje zdravilno učinkovino velagluceraza alfa.
English: Home infusions should be supervised by a healthcare professional trained in emergency measures.
Slovenian: Infundiranje na domu se mora izvajati pod nadzorom zdravstvenega osebja, ki je izurjeno za izredno ukrepanje.
English: Vpriv is used for the long-term treatment of patients with Gaucher disease.
Slovenian: Zdravilo Vpriv se uporablja za dolgotrajno zdravljenje bolnikov z Gaucherjevo boleznijo.
English: It is available as a powder that is made up into a solution for infusion (drip) into a vein.
Slovenian: Na voljo je v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
English: The company that markets Vpriv will provide educational material to all doctors and patients expected to use Vpriv, informing them of how to manage the risk of infusion-related reactions when the medicine is given at home.
Slovenian: Družba, ki trži zdravilo Vpriv, bo vsem zdravnikom in bolnikom, ki naj bi uporabljali to zdravilo, priskrbela izobraževalno gradivo z navodili, kako obvladati tveganja, povezana z infundiranjem, če se zdravilo daje v domači oskrbi.
English: The most common side effects with Vpriv (seen in more than 1 patient in 10) are infusion-related reactions, which include headache, dizziness, hypotension (low blood pressure), hypertension (high blood pressure), nausea (feeling sick), asthenia (weakness) or fatigue (tiredness), and pyrexia (fever) or increased body temperature.
Slovenian: Najpogostejši neželeni učinki zdravila Vpriv (opaženi pri 1 bolniku od 10) so povezani z infundiranjem in vključujejo glavobol, omotico, hipotenzijo (nizek krvni tlak), hipertenzijo (visok krvni tlak), navzejo (slabost), astenijo (šibkost) ali utrujenost ter pireksijo (povišano telesno temperaturo).
English: The full EPAR for Vpriv can be found on the Agency's website under EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Vpriv je na voljo na spletni strani agencije EMA website/Find medicine/Human medicines/European Public Assessment Reports.
English: Vpriv treatment should be supervised by a doctor experienced in managing patients with Gaucher disease.
Slovenian: Zdravljenje z zdravilom Vpriv mora nadzorovati zdravnik, ki ima izkušnje z zdravljenjem bolnikov z Gaucherjevo boleznijo.
English: Without the enzyme, glucocerebroside builds up in the body, typically in the liver, spleen and bone, which produces the symptoms of the disease: anaemia (low red blood cell counts), tiredness, easy bruising and a tendency to bleed, an enlarged spleen and liver, and bone pain and breaks.
Slovenian: Ob odsotnosti encima se glukocerebrozid kopiči v telesu, običajno v jetrih, vranici in kostnem mozgu, to pa vodi do nastanka simptomov bolezni: anemije (znižanega števila rdečih krvničk), utrujenosti, povečane verjetnosti za nastanek hematomov in nagnjenosti h krvavitvam, povečane vranice in jeter ter bolečin v kosteh in zlomov kosti.
English: Vpriv was as effective as imiglucerase at reducing anaemia.
Slovenian: Zdravilo Vpriv je bilo pri zmanjševanju anemije enako učinkovito kot imigluceraza.
English: For the full list of all side effects and restrictions with Vpriv, see the package leaflet.
Slovenian: Za celoten seznam vseh neželenih učinkov in omejitev pri uporabi zdravila Vpriv glejte navodilo za uporabo.
English: What is Vpriv used for?
Slovenian: Za kaj se uporablja zdravilo Vpriv?
English: Gaucher disease occurs because of the lack of an enzyme called glucocerebrosidase.
Slovenian: Gaucherjeva bolezen se pojavi zaradi pomanjkanja encima glukocerebrozidaze.
English: How has Vpriv been studied?
Slovenian: Kako je bilo zdravilo Vpriv raziskano?
English: Gaucher disease is a rare inherited disorder, in which people do not have enough of an enzyme called glucocerebrosidase, which normally breaks down a fat called glucocerebroside.
Slovenian: Gaucherjeva bolezen je redka dedna napaka, pri kateri bolniku primanjkuje encima glukocerebrozidaze, ki razgrajuje maščobni odpadni produkt, imenovan glukocerebrozid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vpriv have also been included in the summary of product characteristics and the package leaflet.
Slovenian: V povzetek glavnih značilnosti zdravila Vpriv in navodila za njegovo uporabo so bili vključeni priporočila in previdnostni ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki za njegovo varno in učinkovito uporabo.
English: How is Vpriv used?
Slovenian: Kako se zdravilo Vpriv uporablja?
English: What is Vpriv?
Slovenian: Kaj je zdravilo Vpriv?
English: How does Vpriv work?
Slovenian: Kako zdravilo Vpriv deluje?
English: They are usually temporary.
Slovenian: Navadno so prehodni.
English: Your doctor will discuss this with you.
Slovenian: O tem se bo zdravnik pogovoril z vami.
English: • Your doctor will advise you of the risks and benefits of taking Ontruzant during pregnancy.
Slovenian: • Zdravnik vam bo svetoval glede tveganj in koristi jemanja zdravila Ontruzant med nosečnostjo.
English: Sometimes, symptoms may improve and then get worse later.
Slovenian: Včasih se lahko simptomi izboljšajo in pozneje spet poslabšajo.
English: Appropriate aseptic technique should be used.
Slovenian: Uporabljati morate ustrezno aseptično tehniko.
English: Allow the vial to stand undisturbed for approximately 5 minutes.
Slovenian: Viala naj stoji pri miru približno 5 minut.
English: The following information is intended for healthcare professionals only
Slovenian: Naslednje informacije so namenjene samo zdravstvenemu osebju:
English: Children and adolescents Ontruzant is not recommended for anyone under the age of 18 years.
Slovenian: Otroci in mladostniki Uporaba zdravila Ontruzant ni priporočljiva za mlajše od 18 let.
English: During pregnancy:
Slovenian: V nosečnosti:
English: AUCss, 0-21 days
Slovenian: AUCss, 0-21 dni
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 15 November 2017
Slovenian: Datum prve odobritve: 15. november 2017
English: The number of infusions you receive will depend on how you respond to the treatment.
Slovenian: Število infuzij, ki jih boste prejeli, bo odvisno od vašega odziva na zdravljenje.
English: Before starting the treatment your doctor will determine the amount of HER2 in your tumour.
Slovenian: Pred začetkom zdravljenja bo zdravnik ugotovil količino HER2 v vašem tumorju.
English: Unopened vials: 4 years.
Slovenian: Neodprte viale: 4 leta
English: The majority of the deaths were due to events related to the underlying cancer.
Slovenian: Večina smrti je bila posledica dogodkov, povezanih z obstoječim rakom.
English: The bioactivity of D7D and the clinical impact of the elevation of this metabolite was unclear.
Slovenian: Biološka aktivnost D7D in klinični vpliv zvišanja tega presnovka sta bila nejasna.
English: This helps your medicine work as well as it can.
Slovenian: To omogoči vašemu zdravilo delovati kar najbolj učinkovito.
English: Doses up to this level were well tolerated.
Slovenian: Odmerke do te ravni so bolniki dobro prenašali.
English: Therefore your doctor may decide to continue to check your heart functions, even after you finish treatment.
Slovenian: Zato se bo mogoče zdravnik odločil za nadaljevanje spremljanja delovanja vašega srca tudi po končanem zdravljenju.
English: (increased muscle tone or tension)
Slovenian: (zvečan mišični tonus ali napetost),